NCT00267020 2020-08-31Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic CancerEli Lilly and CompanyPhase 2 Completed130 enrolled 19 charts